Tvardi Therapeutics (NASDAQ:TVRD) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research report report published on Saturday.

Several other research firms also recently commented on TVRD. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Raymond James Financial lowered shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Tuesday, October 14th. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Finally, BTIG Research decreased their price objective on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, October 13th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

Shares of Tvardi Therapeutics stock opened at $6.58 on Friday. Tvardi Therapeutics has a 1-year low of $5.65 and a 1-year high of $43.65. The stock’s fifty day simple moving average is $30.22.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently bought and sold shares of TVRD. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics during the second quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. New York State Common Retirement Fund bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $92,000. Finally, Bank of America Corp DE bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $399,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.